Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.2425
-0.0052 (-2.10%)
At close: May 12, 2026, 4:00 PM EDT
0.2350
-0.0075 (-3.09%)
Pre-market: May 13, 2026, 8:53 AM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$12,100
Profits / Employee
-$6,050,624
Market Cap
25.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Longeveron | 38 |
| Curis | 24 |
| Lantern Pharma | 16 |
| VYNE Therapeutics | 10 |
| AEON Biopharma | 8 |
| Allarity Therapeutics | 8 |
| Exicure | 8 |
OTLK News
- 19 days ago - Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewsWire
- 20 days ago - Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering - TheFly
- 21 days ago - Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 21 days ago - Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA - TheFly
- 22 days ago - Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics submits formal dispute resolution request to FDA - TheFly
- 5 weeks ago - Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - GlobeNewsWire